ELCC 2017 | Current treatment landscape for neuroendocrine tumors

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the current treatment landscape for neuroendocrine tumors at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. The prognosis for neuroendocrine tumors is not very positive as physicians have been unsuccessful in developing specific targeted therapies. Dr Kerr explains how more investigation is required, especially for treatments that involve biomarker testing.